{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:59:33Z","timestamp":1792821573907,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14884-5","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T10:45:24Z","timestamp":1759229124000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real-world treatment patterns and survival outcomes in metastatic head and neck adenoid cystic carcinoma"],"prefix":"10.1186","volume":"25","author":[{"given":"Hatice","family":"B\u00f6lek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Kayaalp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha Koray","family":"\u015eahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osman Talha","family":"Do\u011fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seher","family":"Y\u00fcksel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumerya","family":"Duru Birgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim Halil","family":"Gullu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa K\u00fcr\u015fat","family":"G\u00f6kcan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sercan","family":"Aksoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatime Arzu","family":"Ya\u015far","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"issue":"5","key":"14884_CR1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005964","volume":"96","author":"D-Q Ouyang","year":"2017","unstructured":"Ouyang D-Q, Liang L-Z, Zheng G-S, Ke Z-F, Weng D-S, Yang W-F, et al. Risk factors and prognosis for salivary gland adenoid cystic carcinoma in southern China: a 25-year retrospective study. Medicine (Baltimore). 2017;96(5):e5964.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"14884_CR2","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/1097-0142(19860201)57:3<519::AID-CNCR2820570319>3.0.CO;2-V","volume":"57","author":"HM Matsuba","year":"1986","unstructured":"Matsuba HM, Spector GJ, Thawley SE, Simpson JR, Mauney M, Pikul FJ. Adenoid cystic salivary gland carcinoma: a histopathologic review of treatment failure patterns. Cancer. 1986;57(3):519\u201324.","journal-title":"Cancer"},{"issue":"18","key":"14884_CR3","doi-asserted-by":"publisher","first-page":"4444","DOI":"10.1002\/cncr.27408","volume":"118","author":"CL Ellington","year":"2012","unstructured":"Ellington CL, Goodman M, Kono SA, Grist W, Wadsworth T, Chen AY, et al. Adenoid cystic carcinoma of the head and neck: incidence and survival trends based on 1973\u20132007 surveillance, epidemiology, and end results data. Cancer. 2012;118(18):4444\u201351.","journal-title":"Cancer"},{"issue":"8","key":"14884_CR4","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.ijom.2013.04.006","volume":"42","author":"M Gao","year":"2013","unstructured":"Gao M, Hao Y, Huang M, Ma D, Luo H, Gao Y, et al. Clinicopathological study of distant metastases of salivary adenoid cystic carcinoma. Int J Oral Maxillofac Surg. 2013;42(8):923\u20138.","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"8","key":"14884_CR5","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.oraloncology.2013.05.004","volume":"49","author":"S van Weert","year":"2013","unstructured":"van Weert S, Bloemena E, van der Waal I, de Bree R, Rietveld DH, Kuik JD, et al. Adenoid cystic carcinoma of the head and neck: a single-center analysis of 105 consecutive cases over a 30-year period. Oral Oncol. 2013;49(8):824\u20139.","journal-title":"Oral Oncol"},{"key":"14884_CR6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.oraloncology.2016.10.018","volume":"65","author":"L Girelli","year":"2017","unstructured":"Girelli L, Locati L, Galeone C, Scanagatta P, Duranti L, Licitra L, et al. Lung metastasectomy in adenoid cystic cancer: is it worth it? Oral Oncol. 2017;65:114\u20138.","journal-title":"Oral Oncol"},{"issue":"18","key":"14884_CR7","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1200\/JCO.18.01859","volume":"37","author":"V Tchekmedyian","year":"2019","unstructured":"Tchekmedyian V, Sherman EJ, Dunn L, Tran C, Baxi S, Katabi N, et al. Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma. J Clin Oncol. 2019;37(18):1529\u201337.","journal-title":"J Clin Oncol"},{"issue":"10","key":"14884_CR8","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1093\/annonc\/mdw287","volume":"27","author":"AL Ho","year":"2016","unstructured":"Ho AL, Dunn L, Sherman E, Fury M, Baxi S, Chandramohan R, et al. A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma. Ann Oncol. 2016;27(10):1902\u20138.","journal-title":"Ann Oncol"},{"issue":"2","key":"14884_CR9","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/hed.23577","volume":"37","author":"DJ Thomson","year":"2015","unstructured":"Thomson DJ, Silva P, Denton K, Bonington S, Mak SK, Swindell R, et al. Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck. Head Neck. 2015;37(2):182\u20137.","journal-title":"Head Neck"},{"issue":"6","key":"14884_CR10","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1093\/annonc\/mdr522","volume":"23","author":"N Chau","year":"2012","unstructured":"Chau N, Hotte S, Chen E, Chin S, Turner S, Wang L, et al. A phase II study of sunitinib in recurrent and\/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. Ann Oncol. 2012;23(6):1562\u201370.","journal-title":"Ann Oncol"},{"issue":"15","key":"14884_CR11","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1002\/cncr.29401","volume":"121","author":"B Keam","year":"2015","unstructured":"Keam B, Kim SB, Shin SH, Cho BC, Lee KW, Kim MK, et al. Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma. Cancer. 2015;121(15):2612\u20137.","journal-title":"Cancer"},{"issue":"15","key":"14884_CR12","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1200\/JCO.22.02221","volume":"41","author":"R Ferrarotto","year":"2023","unstructured":"Ferrarotto R, Sousa LG, Feng L, Mott F, Blumenschein G, Altan M, et al. Phase II clinical trial of axitinib and avelumab in patients with recurrent\/metastatic adenoid cystic carcinoma. J Clin Oncol. 2023;41(15):2843\u201351.","journal-title":"J Clin Oncol"},{"issue":"12","key":"14884_CR13","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/1097-0142(19871215)60:12<2869::AID-CNCR2820601203>3.0.CO;2-Y","volume":"60","author":"AI Dreyfuss","year":"1987","unstructured":"Dreyfuss AI, Clark JR, Fallon BG, Posner MR, Norris CM Jr, Miller D. Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin. Cancer. 1987;60(12):2869\u201372.","journal-title":"Cancer"},{"issue":"2","key":"14884_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.21037\/cco.2020.03.07","volume":"9","author":"H Ha","year":"2020","unstructured":"Ha H, Keam B, Ock C-Y, Heo DS. Efficacy of cyclophosphamide, doxorubicin, and cisplatin for adenoid cystic carcinoma, and their relationship with the pre-chemotherapy tumor growth rate. Chin Clin Oncol. 2020;9(2):15.","journal-title":"Chin Clin Oncol"},{"issue":"6","key":"14884_CR15","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1093\/oxfordjournals.annonc.a010684","volume":"7","author":"L Licitra","year":"1996","unstructured":"Licitra L, Cavina R, Grandi C, Di Palma S, Guzzo M, Demicheli R, et al. Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. Ann Oncol. 1996;7(6):640\u20132.","journal-title":"Ann Oncol"},{"issue":"1","key":"14884_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/hed.24933","volume":"40","author":"MH Hong","year":"2018","unstructured":"Hong MH, Kim CG, Koh YW, Choi EC, Kim J, Yoon SO, et al. Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and\/or metastatic salivary gland cancer of the head and neck. Head Neck. 2018;40(1):55\u201362.","journal-title":"Head Neck"},{"issue":"2","key":"14884_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/019459988609500206","volume":"95","author":"MJ Kaplan","year":"1986","unstructured":"Kaplan MJ, Johns ME, Cantrell RW. Chemotherapy for salivary gland cancer. Otolaryngol Head Neck Surg. 1986;95(2):165\u201370.","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"4","key":"14884_CR18","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0964-1955(97)00026-2","volume":"33","author":"M Hill","year":"1997","unstructured":"Hill M, Constenla D, A\u2019hern R, Henk J, Rhys-Evans P, Breach N, et al. Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma. Oral Oncol. 1997;33(4):275\u20138.","journal-title":"Oral Oncol"},{"issue":"2","key":"14884_CR19","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/cncr.24745","volume":"116","author":"SA Laurie","year":"2010","unstructured":"Laurie SA, Siu LL, Winquist E, Maksymiuk A, Harnett EL, Walsh W, et al. A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer: a trial of the NCIC Clinical Trials Group. Cancer. 2010;116(2):362\u20138.","journal-title":"Cancer."},{"issue":"19","key":"14884_CR20","doi-asserted-by":"publisher","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-21-1061","volume":"27","author":"EJ Kang","year":"2021","unstructured":"Kang EJ, Ahn M-J, Ock C-Y, Lee K-W, Kwon JH, Yang Y, et al. Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma. Clin Cancer Res. 2021;27(19):5272\u20139.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"14884_CR21","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1001\/archotol.129.11.1193","volume":"129","author":"M-W Sung","year":"2003","unstructured":"Sung M-W, Kim KH, Kim J-W, Min Y-G, Seong W-J, Roh J-L, et al. Clinicopathologic predictors and impact of distant metastasis from adenoid cystic carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2003;129(11):1193\u20137.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"14884_CR22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ejca.2020.05.013","volume":"136","author":"S Cavalieri","year":"2020","unstructured":"Cavalieri S, Mariani L, Vander Poorten V, Van Breda L, Cau MC, Vullo SL, et al. Prognostic nomogram in patients with metastatic adenoid cystic carcinoma of the salivary glands. Eur J Cancer. 2020;136:35\u201342.","journal-title":"Eur J Cancer"},{"key":"14884_CR23","doi-asserted-by":"crossref","unstructured":"Roussel-Simonin C, Riet F, Herv\u00e9 G, Bertolus C, Maingon P, Spano J-P, et al. Efficacy and prognostic factors of systemic therapies for metastatic adenoid cystic carcinoma. Am Soc Clin Oncol; 2019","DOI":"10.1200\/JCO.2019.37.15_suppl.e17587"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14884-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14884-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14884-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:29:41Z","timestamp":1759274981000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14884-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14884"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14884-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"6 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Ankara University Faculty of Medicine Ethics Committee (date:10\/02\/2025, decision number: I01-44\u201325) and it was carried out in accordance with the Code of Ethics of the World Medical Association also known as a declaration of Helsinki. Due to the retrospective nature of the study the use of anonymized data, no informed consent was required as per the (Ankara University Faculty of Medicine Ethics Committee) approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1451"}}